Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Hematologic Oncology Update
00:00
Early CAR T experiences and evolution
Dr Matthew Lunning recalls frontline experiences and how management of CRS and ICANS evolved from ICU crises to broader adoption.
Play episode from 00:23
Transcript
